<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="138419">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01299116</url>
  </required_header>
  <id_info>
    <org_study_id>10250</org_study_id>
    <nct_id>NCT01299116</nct_id>
  </id_info>
  <brief_title>Long-Acting Reversible Contraception</brief_title>
  <acronym>LARC</acronym>
  <official_title>Long-Acting Reversible Contraception: New Research to Reduce Unintended Pregnancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>FHI 360</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>FHI 360</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the proposed study, women aged 18-29 seeking oral or injectable contraception will be
      offered an opportunity to try LARC instead; the FDA-approved options include two types of
      intrauterine products and one type of subdermal contraceptive implant. Over a 24 month
      period, the experiences of LARC users will be compared to the experiences of those opting
      for their initial short-acting method.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this partially randomized patient preference study, women aged 18-29 seeking oral or
      injectable contraception will be offered an opportunity to try LARC instead; the
      FDA-approved options include two types of intrauterine products and one type of subdermal
      contraceptive implant. Over a 24-month period, the experiences of LARC users will be
      compared to the experiences of those opting for their initial short-acting method. It is
      expected that 38% of the participants using short-acting methods will stop using them during
      the first year and be at risk of unintended pregnancy. In contrast, less than 20% of LARC
      users will want to have their contraceptive removed. Continuation rates will be measured and
      pregnancies will be tallied in the two groups to document any differences that emerge.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2011</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Contraceptive method discontinuation</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Unintended pregnancy</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Participant attitudes to LARC vs SARC</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">916</enrollment>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>SARC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received one of a variety of oral contraceptives or DMPA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LARC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receive one of the following interventions:
Implanon® or Nexplanon®; ParaGard®; Mirena®</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DMPA</intervention_name>
    <description>Injectable contraceptive, containing 150 mg depot medroxyprogesterone acetate (DMPA) and marketed in the US as Depo-Provera® or containing 104 mg DMPA and marketed as Depo-SubQ Provera 104®.</description>
    <arm_group_label>SARC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oral contraceptives</intervention_name>
    <description>Oral contraceptives (any variety of formulations are permitted)</description>
    <arm_group_label>SARC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Implanon®</intervention_name>
    <description>Subdermal contraceptive implant, marketed in the US as Implanon® or Nexplanon® (containing 68 mg of etonogestrel)</description>
    <arm_group_label>LARC</arm_group_label>
    <other_name>Nexplanon®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ParaGard®</intervention_name>
    <description>Intrauterine device marketed in the US as ParaGard® (a T-shaped plastic device containing 380mm2 of copper surface)</description>
    <arm_group_label>LARC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mirena®</intervention_name>
    <description>Intrauterine system, marketed in the US as Mirena® (containing 52 mg of levonorgestrel)</description>
    <arm_group_label>LARC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 to 29 years of age;

          -  sexually active;

          -  seeking oral or injectable contraception;

          -  working cell phone;

          -  working email account;

          -  willingness to be contacted by the clinic staff or study coordinators; and,

          -  willingness to complete questionnaires.

        Exclusion Criteria:

          -  currently pregnant;

          -  previous use of a long-acting reversible contraceptive (LARC) method; and,

          -  medical contraindications for oral contraceptives and injectables.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>29 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Hubacher, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>FHI 360</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Planned Parenthood Central North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>February 1, 2017</lastchanged_date>
  <firstreceived_date>February 16, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AE adverse event</keyword>
  <keyword>FDA (U.S.) Food and Drug Administration</keyword>
  <keyword>GCP Good Clinical Practice guidelines</keyword>
  <keyword>ICH International Conference of Harmonisation</keyword>
  <keyword>IRB Institutional Review Board</keyword>
  <keyword>IU International units</keyword>
  <keyword>mg milligram(s)</keyword>
  <keyword>mm3 cubic millimeter(s)</keyword>
  <keyword>LARC Long-Acting reversible contraception</keyword>
  <keyword>PPCNC Planned Parenthood of North Carolina</keyword>
  <keyword>SAE serious adverse event</keyword>
  <keyword>SARC Short-Acting reversible contraception</keyword>
  <keyword>µg microgram</keyword>
  <keyword>ULN upper limit of the normal range</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Contraceptives, Oral</mesh_term>
    <mesh_term>Levonorgestrel</mesh_term>
    <mesh_term>Etonogestrel</mesh_term>
    <mesh_term>Contraceptive Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
